证券代码：688336 证券简称：三生国健 公告编号：2025-020 三生国健药业（上海）股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 15 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区李冰 路 399 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的 优先股股东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 普通股股东人数 | 107 | | 2、出席会议的股东所持有的表决权数量 | 541,837,377 | | 普通股股东所持有表决权数量 | 541,837,377 | | 3、出席会议的股东所持有表决权数量占公司表决权 | 87.8485 | | --- | --- | | 数量的比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

国浩律师(上海)事务所 法律资见书 国浩律师（上海）事务所 关于三生国健药业(上海)股份有限公司 2024 年年度股东大会的 法律意见书 致:三生国健药业（上海）股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）的规定，围浩律师（上海 ) 事务所接受三生国健药业(上海)股份有限公司(以下简称"公司")董事会的 聘请，指派律师现场见证了公司于 2025 年 4 月 15 门 10:00 起在中国（上海）自由 贸易试验区李冰路 399 号公司会议室召开的公司 2024年年度股东大会,并依据有 关法律、法规、规范性文件的规定以及《三生国健药业（上海）股份有限公司章 程》（以下简称"《公司竟程》"）的规定，对本次股东大会的召集、召开程序、 出席人员资格、大会表决程序等事宜进行了审查，现发表法律意见如下: 一、股东大会的召集、召开程序 公司董事会已于 2025年 3 月 26 日在中国证监会指定信息披露网站上向公司 股东发出了召开 2024年年度股东大会的会议通知。经核查 ...

Core Viewpoint - Recently, Sangon Biotech (Shanghai) Co., Ltd. received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing the company to conduct Phase I clinical trials for SSGJ-627 injection for ulcerative colitis (UC) [2][3]. Group 1: Drug Information - SSGJ-627 injection is an innovative recombinant anti-TL1A humanized monoclonal antibody developed by the company, with independent intellectual property rights [3]. - TL1A is a member of the tumor necrosis factor superfamily, primarily expressed by endothelial cells, and plays a crucial role in mucosal immune response, allergies, and autoimmune diseases [3]. - The drug has received Phase I clinical trial approvals in both China and the United States, making it the first domestically developed TL1A antibody to obtain an IND approval [3]. - Preclinical studies have shown that SSGJ-627 has high affinity and specificity for TL1A, demonstrating significant efficacy in various animal models, along with good safety and tolerability [3].

Summary of Conference Call Records Company and Industry Overview - The conference call discusses the performance and strategic direction of a company in the innovative pharmaceutical sector, particularly focusing on autoimmune diseases and the development of new therapies. The company reported a revenue of 1.2 billion yuan, representing an 18% year-over-year growth, and a net profit increase of 139.15% [1][4]. Key Points and Arguments Industry Dynamics - 2024 is highlighted as a pivotal year for China's innovative drug industry, driven by national health strategies and local policy support, which are reshaping the industry ecosystem [1]. - The company is transitioning from being a participant to a leader in the global innovative drug market, with significant growth in clinical trial numbers and international collaborations [1]. Product Development and Pipeline - The company has established a comprehensive product matrix in the autoimmune field, with an increasing proportion of innovative molecules and several new products poised for launch [2]. - The company plans to enhance its clinical breakthroughs and develop AI-driven drug platforms, aiming for a technological leap in autoimmune research [2]. - The company has 22 products in its pipeline, with several in various stages of clinical trials, including promising results from ongoing studies [5][12]. Financial Performance - The company increased its R&D investment to 540 million yuan, a 72% growth, while maintaining profitability, indicating a trend of sustainable growth [4][27]. - Cash reserves have grown to 3.3 billion yuan due to increased net profits, reflecting a strong financial position [4]. Clinical Trials and Results - The company reported positive results from multiple clinical trials, including significant efficacy in treating conditions like psoriasis and chronic obstructive pulmonary disease (COPD) [13][15]. - The company is actively pursuing new clinical trials for various autoimmune conditions, with several products showing superior efficacy compared to competitors [17][18]. Management and ESG Initiatives - The management team has been strengthened with new talent, including experienced scientists, to drive clinical and operational excellence [9]. - The company emphasizes its commitment to ESG (Environmental, Social, and Governance) standards, achieving high ratings and focusing on social responsibility alongside financial growth [8]. Future Outlook - The company aims to maintain its focus on innovation and internationalization, with plans to develop first-in-class and best-in-class products [27]. - There is a strategic emphasis on building a differentiated commercialization system and exploring potential collaborations to enhance growth [27]. Additional Important Content - The company is exploring advanced treatment modalities, including dual-target therapies for autoimmune diseases, which could position it as a leader in the market [24][25]. - The company is also investigating the potential for immune cell clearance as a new treatment approach, aiming for a future where autoimmune diseases can be cured [26]. This summary encapsulates the key insights from the conference call, highlighting the company's strategic initiatives, financial health, and commitment to innovation in the pharmaceutical industry.

Group 1 - The core viewpoint is that the company Sanofi Guojian is expected to achieve steady revenue growth in 2025, with significant clinical data releases anticipated [1] - The company has received acceptance for the ND application of the 608 project by CDE, indicating progress in its development pipeline [1] - Research and development investment for 2024 is projected to be 540 million yuan, reflecting a 72% year-on-year increase due to more projects entering late-stage clinical trials [1] Group 2 - The IBD market in China is estimated to have around 1.5 to 2 million patients, suggesting a potential for rapid growth as major companies are already making investments in this area [1]

Core Viewpoint - The company is preparing for its 2024 annual general meeting, outlining the procedures and agenda for the meeting, including various proposals for shareholder approval [1][2][3]. Meeting Procedures - The meeting will ensure the presence of relevant stakeholders, including shareholders, directors, supervisors, and invited guests, while excluding unrelated personnel [1][2]. - Shareholders must register and present necessary documentation to participate in the voting process, with late arrivals not permitted to vote [2][3]. - The meeting will follow a predetermined agenda for discussing and voting on proposals [2][3]. Proposals for Approval - Proposal 1: The board's work report for 2024 has been prepared and submitted for shareholder review [5]. - Proposal 2: The financial settlement report for 2024 has been created and is ready for approval [5]. - Proposal 3: The financial budget report for 2025 has been prepared for shareholder consideration [6]. - Proposal 4: The annual report for 2024 is submitted for approval [6]. - Proposal 5: The reappointment of Ernst & Young Hua Ming as the auditing firm for 2025 is proposed [7]. - Proposal 6: A profit distribution plan for 2024 is proposed, with a cash dividend of RMB 0.90 per share [8][9]. - Proposal 7: The remuneration plan for directors in 2025 is outlined, with independent directors receiving RMB 100,000 annually [10]. - Proposal 8: The execution of related party transactions for 2024 and projections for 2025 are presented, ensuring compliance with regulations and fair pricing [11][21]. Financial Performance - The company reported a net profit of RMB 704.58 million for 2024, with an unallocated profit of RMB 2.28 billion as of December 31, 2024 [25]. - The total revenue for 2024 was RMB 1.19 billion, reflecting a stable growth trajectory [25]. - The company’s operating costs increased to RMB 304.34 million, a rise of 35.80% compared to the previous year, primarily due to increased sales volumes [25]. Governance and Compliance - The board of directors has adhered to legal requirements and company regulations in conducting meetings and decision-making processes [27][28]. - The company has established a robust internal control system to enhance governance and risk management [31].

证券代码： 688336 证券简称：三生国健 公告编号：2025-019 三生国健药业（上海）股份有限公司 关于自愿披露公司获得《药物临床试验批准通知书》 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，三生国健药业（上海）股份有限公司（以下简称"公司" 或"三生国健"）SSGJ-627 注射液收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的《药物临床试验批准通知书》，同 意公司开展 SSGJ-627 注射液溃疡性结肠炎（UC）的 I 期临床试验。 一、药品基本情况 1 | | 查，2025 | 年 | 1 | 月 | 8 | 日受理的 | SSGJ-627 | 注射液临床试验 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 申请符合药品注册的有关要求，同意本品开展临床试 | | | | | | | | | | 验。 | | | | | | | | | | 申请的适应症：溃疡性结肠炎（UC）。 | | | ...

2024 年年度股东大会会议资料 证券代码： 688336 证券简称：三生国健 三生国健药业（上海）股份有限公司 2024 年年度股东大会会议资料 二〇二五年四月 1 | 目录 | | --- | | 2024 | 年年度股东大会会议须知 3 | | --- | --- | | 2024 | 年年度股东大会会议议程 6 | | 2024 | 年年度股东大会会议议案 9 | | 议案 | 1、《关于公司<2024 年度董事会工作报告>的议案》 9 | | 议案 | 2、《关于公司<2024 年度财务决算报告>的议案》 10 | | 议案 | 3、《关于公司<2025 年度财务预算报告>的议案》 11 | | 议案 | 4、《关于公司<2024 年年度报告及摘要>的议案》 12 | | 议案 | 5、《关于续聘公司 2025 年度审计机构的议案》 13 | | 议案 | 6、《关于公司<2024 年年度利润分配方案>的议案》 14 | | 议案 | 7、《关于公司 2025 年度董事薪酬的议案》 16 | | 议案 | 8、《关于公司 2024 年度日常关联交易执行情况及 2025 年度日常关联交易预计的 | | ...

Group 1 - The stock of Sanofi (三生国健688336) has a comprehensive score of 60.82, indicating a strong performance [1] - The main cost analysis shows the current price at 29.23 CNY, with a 5-day cost of 27.83 CNY and a 20-day cost of 24.28 CNY [1][3] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - The short-term resistance level is at 28.04 CNY, while the short-term support level is at 26.95 CNY [2] - The stock price has broken through the short-term resistance level, suggesting a potential short-term strength [2][3] - The K-line pattern indicates a "Red Three Soldiers" formation, suggesting a possible bottoming out and recovery [2][3] Group 3 - On April 1, 2025, the net inflow of main funds was 14.66 million CNY, accounting for 7% of the total transaction volume [2] - Large orders saw a net inflow of 18.18 million CNY, while super large orders experienced a net outflow of 3.52 million CNY [2][3] - Retail investors contributed a net inflow of 502,100 CNY [2] Group 4 - The latest financial data shows earnings per share at 0.38 CNY, with an operating profit of 262 million CNY [2] - The gross profit margin stands at 71.259%, with a net profit of 222.76 million CNY [2][3] - The stock is associated with sectors such as bioproducts (4.38%), monoclonal antibodies (4.73%), and recombinant proteins (5.50%) [2]

Core Insights - In 2024, the company reported a revenue increase of 17.70% to 1.194 billion yuan and a net profit surge of 139.15% to 705 million yuan, indicating strong financial performance despite underlying challenges [1] - The company faces significant pressure on its core product due to expanded centralized procurement and shrinking market share, with a projected net profit drop of 57.42% in 2025 attributed to profit margin compression from procurement [2] - The company's strategy of divesting non-core businesses has led to a concentration in the autoimmune sector, raising concerns about pipeline risk and growth sustainability, as only three products currently support its performance [3] - The company's R&D investment remains insufficient compared to peers, with a reliance on early-stage projects from related parties potentially posing governance risks [4] - The company's transformation reflects broader challenges faced by Chinese innovative pharmaceutical companies, emphasizing the need for sustainable growth without relying on non-recurring income [5] Financial Performance - Revenue for 2024 reached 1.194 billion yuan, a 17.70% year-on-year increase [1] - Net profit for 2024 was 705 million yuan, a 139.15% increase compared to the previous year [1] - Operating cash flow for 2024 decreased by 32.48% to 281 million yuan, indicating cash flow concerns [2] Market Challenges - The core product, Yisaipu, has seen its market share decline from 40.14% in 2016 to 27.00% in 2022 due to price reductions from centralized procurement [2] - The company anticipates a significant profit drop in 2025 due to ongoing pricing pressures and increased competition from new drug entrants [2] Strategic Focus - The company has divested from oncology and ophthalmology pipelines to concentrate on the autoimmune sector, but this has led to a narrow product focus [3] - The future growth potential in the autoimmune market is promising, with projections estimating a market size of $19.9 billion by 2030, but the company faces challenges in overcoming competition and achieving successful new drug launches [3] R&D and Governance - The company has not disclosed specific R&D expenses for 2024, but acknowledges rising costs due to rapid project advancement [4] - Compared to peers, the company's R&D expense ratio is low, raising concerns about its innovation capacity [4] - Increased dependency on related party transactions may lead to governance issues and affect investor confidence [4]